Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia

類似資料

• Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
  著者:: Vyas, P, 等
  出版事項: (2018)
• Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
  著者:: Amatangelo, MD, 等
  出版事項: (2017)
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
  著者:: Stein, EM, 等
  出版事項: (2017)
• Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
  著者:: Risueño, A, 等
  出版事項: (2024)
• Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
  著者:: Risueño, A, 等
  出版事項: (2023)